Acurian: new consulting service provides 'continuum of support'

(Image: iStock/DigtialStorm)

Acurian Inc. has launched a new consulting offering to help pharma sponsors throughout protocol design, enrollment, site planning, and budgeting.

The patient enrollment and retention solution provider, and PPD subsidiary, has announced Acurian Consulting Services, which the company said formalizes its patient-centric perspective on trial planning.

Through Acurian Consulting Services, clients are able to benefit from a continuum of support that can help them successfully design their molecule projects or programs,” a company spokesperson told Outsorucing-Pharma.com.

That includes leveraging enrollment and patient feasibility data to assist clients in planning for global, Phase III programs and influencing development of central recruitment strategy, as well as leveraging access to patients to help clients gather patient feedback on protocol and study designs.”

According to the company, the new services provide patient-centric, data-driven insights to help drive protocol design, patient enrollment feasibility, site and country planning, and budgeting for central recruitment.

These services are another way Acurian is expanding its data mining and aggregation competencies to facilitate modeling and simulation,” the spokesperson added. “These capabilities provide more reliable information, more quickly guide site selection and recruitment planning, and centralize country and site selection.”

Related News

Accenture provides cloud-based clinical data aggregation and exchange platforms for pharmaceutical clients. (Image: iStock/JK1991)

Advanced tech, data will lead to new patient treatments, says Accenture

(Image: iStock/lovelyday12)

CRO PharPoint Research expands consulting services

Certara has expanded its Strategic Consulting (CSC) division through its acquisition of d3 Medicine. (Image: iStock/ikko Lemola)

Drug development consultancy Certara focusing on 'value based development'

The medical device CRO market could reach nearly $13bn by 2023. (Image: iStock/NicoElNino)

Medical device CROs: the next growth opportunity?

Clinical SCORE provides the pharmaceutical industry with analytics to advance drug development. (Image: iStock/Davizro)

'Partner of Choice' aims to quantify medical affairs initiatives